Trial Profile
Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Lutetium-177-DOTA-girentuximab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jun 2017 New trial record